Covered recipient · General Payments record
SAIMA CHOHAN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,971.41
272 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,852.80 | 270 |
| Education | $118.61 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $593.21 | 35 |
| AbbVie, Inc. | $576.27 | 35 |
| PFIZER INC. | $557.60 | 38 |
| Lilly USA, LLC | $479.94 | 49 |
| Novartis Pharmaceuticals Corporation | $281.97 | 13 |
| Genentech USA, Inc. | $244.00 | 20 |
| UCB, Inc. | $199.91 | 13 |
| GENZYME CORPORATION | $168.64 | 9 |
| E.R. Squibb & Sons, L.L.C. | $152.94 | 9 |
| Janssen Biotech, Inc. | $151.68 | 13 |
| Horizon Therapeutics plc | $129.70 | 11 |
| GlaxoSmithKline, LLC. | $80.73 | 6 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65.66 | 4 |
| Celgene Corporation | $56.05 | 4 |
| Sobi, Inc | $49.75 | 2 |
| Merck Sharp & Dohme Corporation | $42.19 | 3 |
| Alexion Pharmaceuticals, Inc. | $32.36 | 2 |
| Mallinckrodt Enterprises LLC | $27.25 | 1 |
| ASSERTIO THERAPEUTICS, Inc. | $20.62 | 1 |
| Flexion Therapeutics, Inc. | $18.34 | 1 |
| Radius Health, Inc. | $16.14 | 1 |
| Janssen Pharmaceuticals, Inc | $14.30 | 1 |
| Hikma Pharmaceuticals USA | $12.16 | 1 |
Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SAIMA CHOHAN
NPI 1073675526 · CMS profile ID 140219
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SAIMA CHOHAN, NPI 1073675526, CMS profile ID 140219, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 272 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073675526?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
272 matching records · $3,971.41 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 272.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $30.96 | 06/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990090 | CMS |
| Celgene Corporation | $10.87 | 06/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672859870 | CMS |
| Lilly USA, LLC | $17.37 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658142435 | CMS |
| Lilly USA, LLC | $2.10 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658132341 | CMS |
| UCB, Inc. | $5.51 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688328717 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.08 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651226683 | CMS |
| PFIZER INC. | $17.05 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672430253 | CMS |
| Horizon Therapeutics plc | $12.99 | 05/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691349945 | CMS |
| Lilly USA, LLC | $5.94 | 05/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658132339 | CMS |
| Novartis Pharmaceuticals Corporation | $16.25 | 05/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659139079 | CMS |
| Merck Sharp & Dohme Corporation | $12.34 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695859185 | CMS |
| PFIZER INC. | $0.38 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672468823 | CMS |
| PFIZER INC. | $12.37 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672472412 | CMS |
| AbbVie, Inc. | $14.91 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647777137 | CMS |
| Horizon Therapeutics plc | $3.51 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691349941 | CMS |
| Lilly USA, LLC | $4.52 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658125503 | CMS |
| Lilly USA, LLC | $20.28 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658139155 | CMS |
| Lilly USA, LLC | $2.49 | 05/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658132337 | CMS |
| Lilly USA, LLC | $15.87 | 05/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658145489 | CMS |
| Lilly USA, LLC | $4.77 | 05/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658145491 | CMS |
| AbbVie, Inc. | $12.73 | 05/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647777129 | CMS |
| PFIZER INC. | $14.08 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672485483 | CMS |
| PFIZER INC. | $15.53 | 05/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672481429 | CMS |
| GENZYME CORPORATION | $18.13 | 05/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694050155 | CMS |
| Lilly USA, LLC | $5.02 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658129019 | CMS |
| Lilly USA, LLC | $15.34 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658132335 | CMS |
| AbbVie, Inc. | $20.44 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647777021 | CMS |
| Novartis Pharmaceuticals Corporation | $7.05 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659139095 | CMS |
| PFIZER INC. | $13.95 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672413153 | CMS |
| Sobi, Inc | $23.65 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698090789 | CMS |
| Merck Sharp & Dohme Corporation | $18.76 | 05/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695859187 | CMS |
| Amgen Inc. | $23.87 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990129 | CMS |
| Amgen Inc. | $23.36 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990034 | CMS |
| PFIZER INC. | $19.61 | 04/30/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672491151 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651226681 | CMS |
| Janssen Biotech, Inc. | $12.02 | 04/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658371123 | CMS |
| Horizon Therapeutics plc | $12.72 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691349939 | CMS |
| PFIZER INC. | $13.70 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672477907 | CMS |
| Amgen Inc. | $1.21 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990029 | CMS |
| Amgen Inc. | $7.09 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990125 | CMS |
| Genentech USA, Inc. | $1.63 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681160644 | CMS |
| GENZYME CORPORATION | $20.77 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694004107 | CMS |
| Amgen Inc. | $18.65 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990087 | CMS |
| Amgen Inc. | $5.20 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662990023 | CMS |
| Horizon Therapeutics plc | $5.84 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691349937 | CMS |
| Lilly USA, LLC | $2.49 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658135797 | CMS |
| Lilly USA, LLC | $21.55 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658139153 | CMS |
| PFIZER INC. | $8.84 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672465539 | CMS |
| GENZYME CORPORATION | $18.41 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694036085 | CMS |
| PFIZER INC. | $12.60 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672430147 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $931,082.46 | 54 |
| PY2024 | Principal investigator | $339,887.91 | 85 |
| PY2023 | Principal investigator | $137,565.67 | 36 |
| PY2022 | Principal investigator | $85,206.39 | 63 |
| PY2021 | Principal investigator | $150,189.20 | 89 |
| PY2020 | Principal investigator | $130,022.48 | 52 |
| PY2019 | Principal investigator | $137,479.44 | 46 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
54 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,080.70 | 12/01/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289140 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,080.70 | 11/19/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288595 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,962.80 | 11/07/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430758 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $55.90 | 10/27/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430700 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 10/24/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223287645 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,395.80 | 10/03/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286349 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,040.00 | 10/03/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286351 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,517.23 | 10/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430722 |
| Principal investigator 1 | Amgen Inc. | $8,770.95 | 08/25/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246639205 |
| Principal investigator 1 | Amgen Inc. | $31,771.45 | 07/16/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246639269 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $325.00 | 07/14/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430764 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,788.20 | 07/11/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430744 |
| Principal investigator 1 | ARGENX US, INC. | $1,544.40 | 07/09/2025 | Non-covered Recipient Entity Arizona Arthritis & Rheumatology Research, PLLC | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis | No dispute reported | 06/30/2026 | 1237146602 |
| Principal investigator 1 | Amgen Inc. | $114,294.79 | 07/07/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639293 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $677.30 | 07/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430710 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,998.02 | 06/25/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430680 |
| Principal investigator 1 | ARGENX US, INC. | $4,861.50 | 06/18/2025 | Non-covered Recipient Entity Arizona Arthritis & Rheumatology Research, PLLC | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis | No dispute reported | 06/30/2026 | 1237146598 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,467.45 | 06/11/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430730 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $209.30 | 06/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430702 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,000.00 | 05/22/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. | No dispute reported | 06/30/2026 | 1246430814 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $120.00 | 05/21/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430686 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $495.14 | 05/12/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430800 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,200.00 | 05/08/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. | No dispute reported | 06/30/2026 | 1246430810 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $623.10 | 05/07/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430738 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $315.93 | 05/07/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430796 |
| Principal investigator 1 | Amgen Inc. | $23,567.99 | 05/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246639231 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $500.00 | 04/23/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430770 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $400.40 | 04/22/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. | No dispute reported | 06/30/2026 | 1246430812 |
| Principal investigator 1 | Amgen Inc. | $450.00 | 04/18/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246639257 |
| Principal investigator 1 | Amgen Inc. | $9,654.88 | 04/08/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS CLINIC - CHANDLER | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639333 |
| Principal investigator 1 | Amgen Inc. | $71,686.05 | 04/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639247 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $140.40 | 04/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430774 |
| Principal investigator 1 | Amgen Inc. | $22,662.45 | 03/19/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639211 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,273.10 | 03/17/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430752 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15,947.10 | 03/14/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430684 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,321.35 | 03/10/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430694 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,119.74 | 03/06/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430794 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,265.02 | 03/05/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS & RHEUMATOL | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1185545029 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $373.10 | 03/03/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430728 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,105.00 | 02/26/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223275681 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,101.00 | 02/22/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430788 |
| Principal investigator 1 | Amgen Inc. | $11,931.00 | 02/21/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - MESA - 2152 S VINEYARD | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246639221 |
| Principal investigator 1 | ARGENX US, INC. | $17,900.00 | 02/14/2025 | Non-covered Recipient Entity Arizona Arthritis & Rheumatology Research, PLLC | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis | No dispute reported | 06/30/2026 | 1237146381 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $316.05 | 02/12/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430786 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $13,787.80 | 02/05/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430716 |
| Principal investigator 1 | Amgen Inc. | $22,830.00 | 02/03/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH | A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246639303 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $674.70 | 02/03/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430768 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $269.40 | 01/28/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430784 |
| Principal investigator 1 | Amgen Inc. | $10,881.00 | 01/17/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246639209 |
| Principal investigator 1 | Amgen Inc. | $9,340.99 | 01/17/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH | A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1246639261 |
| Principal investigator 1 | Amgen Inc. | $21,820.14 | 01/08/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639213 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,871.50 | 01/08/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1185545031 |
| Principal investigator 1 | Amgen Inc. | $363,151.68 | 01/02/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS CLINIC - CHANDLER | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246639337 |
| Principal investigator 1 | Amgen Inc. | $60,044.96 | 01/02/2025 | Non-covered Recipient Entity ARIZONA RESEARCH CLINIC PLLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246639347 |